One stock that might be an intriguing choice for investors right now is BioTime, Inc. BTX. This is because this security in the Medical-Biomedical/Genetics space is seeing solid earnings estimate ...
ALAMEDA, Calif.--(BUSINESS WIRE)-- BioTime, Inc. (NYSE MKT: BTX) and its recently formed subsidiary BioTime Acquisition Corporation (BAC) jointly announced today that they have entered into a ...
Adds senior executive with significant experience in sales and marketing of research products ALAMEDA, Calif.--(BUSINESS WIRE)-- BioTime, Inc. (NYSE MKT: BTX) today announced the appointment of ...
BioTime, Inc.Peter Garcia, 510-521-3390, ext 367Chief Financial OfficerorJudith Segall, 510-521-3390, ext 301orLifeMap Sciences, Inc.Kenneth Elsner, 781-826-7719COO BioTime, Inc. (NYSE MKT: BTX) and ...
Stem cell technology developer Cell Targeting has sold its assets to BioTime (AMEX:BTX) in a deal worth about $2.3 million. BioTime will pay $250,000 in cash as well as 262,000 shares of BioTime’s ...
ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, has licensed one of its pluripotent cell lines to Goliver ...
ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today reported financial results for the first quarter ...
A look at the shareholders of BioTime Inc (NYSEMKT:BTX) can tell us which group is most powerful. Institutions will often hold stock in bigger companies, and we expect to see insiders owning a ...
Resource is expected to help researchers select the most suitable progenitor cell lines. Regenerative medicines firm BioTime has teamed up with XenneX to establish LifeMap Sciences, an intiiative that ...
ALAMEDA, Calif.--(BUSINESS WIRE)-- BioTime, Inc. (NYSE Amex: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief ...
Alameda-based BioTime, which has seen its stock double in the past year, reached an agreement this week to provide important embryonic stem cell lines to California-based researchers for free in hopes ...
Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biotechnology company BioTime (NYSEMKT: BTX) has received the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results